Point-of-care HIV viral load in pregnant women without prenatal care: a cost-effectiveness analysis

American Journal of Obstetrics and Gynecology

Volumn 221, Issue 3, 2019, Pages 265.e1-265.e9

  Avram, Carmen M ^a   Greiner, Karen S ^a   Tilden, Ellen ^a,b   Caughey, Aaron B ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

biomarker; cesarean; HIV testing; mother to child transmission; point of care test; pregnancy outcomes; rapid test; vertical transmission; viral load

Indexed keywords

VIRUS RNA;

ADULT; ARTICLE; CESAREAN SECTION; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION TREE; FEMALE; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MATERNAL CARE; NEWBORN; NONHUMAN; POINT OF CARE TESTING; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; VAGINAL DELIVERY; VIRUS LOAD; VIRUS TRANSMISSION; COST BENEFIT ANALYSIS; ECONOMICS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; OBSTETRIC DELIVERY; POINT OF CARE SYSTEM; PREGNANCY; PREGNANCY COMPLICATION; PREVENTION AND CONTROL; PROCEDURES; UNITED STATES; VERTICAL TRANSMISSION; VIROLOGY;

ADULT; CESAREAN SECTION; COST-BENEFIT ANALYSIS; DECISION TREES; DELIVERY, OBSTETRIC; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; POINT-OF-CARE SYSTEMS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; QUALITY-ADJUSTED LIFE YEARS; RNA, VIRAL; UNITED STATES; VIRAL LOAD;

EID: 85071647860     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2019.06.021     Document Type: Article

References (47)

1. Garcia, P.M.1, Kalish, L.A., Pitt, J., et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 341 (1999), 394–402.
2. Ioannidis, J.P., Abrams, E.J., Ammann, A., et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. J Infect Dis 183 (2001), 539–545.
3. Warszawski, J., Tubiana, R., Le Chenadec, J., et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 22 (2008), 289–299.
4. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. November 14, 2017 [cited 2018 October 18]. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. (Accessed 18 October 2018)
5. Momplaisir, F.M., Brady, K.A., Fekete, T., et al. Time of HIV diagnosis and engagement in prenatal care impact virologic outcomes of pregnant women with HIV. PLoS One, 10, 2015, e0132262.
6. Ng, R., Macdonald, E.M., Loutfy, M.R., et al. Adequacy of prenatal care among women living with human immunodeficiency virus: a population-based study. BMC Public Health, 15, 2015, 514.
7. European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 353 (1999), 1035–1039.
8. International Perinatal HIV Group Andiman, W., Bryson, Y., de Martino, M., et al. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1—a meta-analysis of 15 prospective cohort studies. N Engl J Med 340 (1999), 977–987.
9. ACOG, American College of Obstetricians and Gynecologists. Labor and delivery management of women with human immunodeficiency virus infection. ACOG Committee Opinion No. 751. Obstet Gynecol 2018 (2018), 131–137.
10. Quest Diagnostics. HIV-1 RNA, Quantitative, Real-Time PCR 2017. Available at: www.questdiagnostics.com. (Accessed 18 October 2018)
11. Oregon Health & Science University Lab. HIV-1 Genotype with Viral Load. Available at: https://www.ohsu.edu/xd/health/services/lab-services/labtests/. (Accessed 18 October 2018)
12. Dorward, J., Drain, P.K., Garrett, N., Point-of-care viral load testing and differentiated HIV care. Lancet HIV 5 (2018), e8–e9.
13. Garrett, N.J., Drain, P.K., Werner, L., Samsunder, N., Abdool Karim, S.S., Diagnostic accuracy of the Point-of-care Xpert(®) HIV-1 Viral Load Assay in a South African HIV clinic. J Acquir Immune Defic Syndr 72 (2016), e45–e48.
14. Moyo, S., Mohammed, T., Wirth, K.E., et al. Point-of-Care Cepheid Xpert HIV-1 Viral Load Test in rural African communities is feasible and reliable. J Clin Microbiol 54 (2016), 3050–3055.
15. Nash, M., Huddart, S., Badar, S., et al. Performance of the Xpert HIV-1 Viral Load Assay: a systematic review and meta-analysis. J Clin Microbiol, 56, 2018 e01673-17.
16. WHO. Xpert® HIV-1 Viral Load with GeneXpert® Dx, GeneXpert® Infinity48, GeneXpert® Infinity-48s and GeneXpert® Infinity-80 2017 [cited 2018 08/03/2018]. Available at: http://www.who.int/diagnostics_laboratory/evaluations/pq-list/hiv-vrl/170720_final_pq_report_pqdx_0192_0193_0194_0195_070-00.pdf?ua=1. (Accessed 3 August 2018)
17. The Annie, E., Casey Foundation. Kids Count Data Center. Births to women receiving late or no prenatal care. 2016 [cited 2018 08/03/18]. Available at: https://datacenter.kidscount.org/data/tables/9078-births-to-women-receiving-late-or-no-prenatal-care-by-race-and-ethnicity#detailed/1/any/false/573,869,36,868,867,133,38,35,18/10,11,9,12,1,13/18064,18065. (Accessed 3 August 2018)
18. Mrus, J.M., Tsevat, J., Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care. Med Decis Making 24 (2004), 30–39.
19. Thompson, D.R., Momplaisir, F.M., Adams, J.W., et al. Mode of delivery among HIV-infected pregnant women in Philadelphia, 2005-2013. PLoS One, 10, 2015, e0144592.
20. Martin, J.A., Hamilton, B.E., Osterman, M.J.K., et al. Births: final data for 2015. National vital statistics report; vol 66, no 1. 2017, National Center for Health Statistics, Hyattsville, MD.
21. Clark, S.L., Belfort, M.A., Dildy, G.A., et al. Maternal death in the 21st century: causes, prevention, and relationship to cesarean delivery. Am J Obstet Gynecol 199 (2008), 36.e1–36.e5 discussion 91-2. e7-11.
22. Landon, M.B., Hauth, J.C., Leveno, K.J., et al. Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery. N Engl J Med 351 (2004), 2581–2589.
23. Declercq, E., Barger, M., Cabral, H.J., et al. Maternal outcomes associated with planned primary cesarean births compared with planned vaginal births. Obstet Gynecol 109 (2007), 669–677.
24. Guise, J.M., Eden, K., Emeis, C., et al. Vaginal birth after cesarean: new insights [review]. Evid Rep Technol Assess (Full Rep) 191 (2010), 1–397.
25. Chauhan, S.P., Martin, J.N. Jr., Henrichs, C.E., et al. Maternal and perinatal complications with uterine rupture in 142,075 patients who attempted vaginal birth after cesarean delivery: a review of the literature. Am J Obstet Gynecol 189 (2003), 408–417.
26. Rossi, A.C., Lee, R.H., Chmait, R.H., Emergency postpartum hysterectomy for uncontrolled postpartum bleeding: a systematic review. Obstet Gynecol 115 (2010), 637–644.
27. Gebo, K.A., Fleishman, J.A., Conviser, R., et al. Contemporary costs of HIV health care in the HAART era. AIDS 24 (2010), 2705–2715.
28. Chung, A., Macario, A., El-Sayed, Y.Y., Riley, E.T., Duncan, B., Druzin, M.L., Cost-effectiveness of a trial of labor after previous cesarean. Obstet Gynecol 97 (2001), 932–941.
29. Angeja, A.C., Washington, A.E., Vargas, J.E., Gomez, R., Rojas, I., Caughey, A.B., Chilean women's preferences regarding mode of delivery: which do they prefer and why?. BJOG 113 (2006), 1253–1258.
30. Mrus, J.M., Goldie, S.J., Weinstein, M.C., Tsevat, J., The cost-effectiveness of elective cesarean delivery for HIV-infected women with detectable HIV RNA during pregnancy. AIDS 14 (2000), 2543–2552.
31. Carroll, A.E., Downs, S.M., Improving decision analyses: parent preferences (utility values) for pediatric health outcomes. J Pediatr 155 (2009), 21–25 25.e1-5.
32. Schackman, B.R., Goldie, S.J., Freedberg, K.A., Losina, E., Brazier, J., Weinstein, M.C., Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making 22 (2002), 27–38.
33. Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV 4 (2017), e349–e356.
34. Xu, J.Q., Murphy, S.L., Kochanek, K.D., Arias, E., Mortality in the United States, 2015. NCHS data brief, no 267. 2016, National Center for Health Statistics, Hyattsville, MD.
35. Albers, L.L., Schiff, M., Gorwoda, J.G., The length of active labor in normal pregnancies. Obstet Gynecol 87 (1996), 355–359.
36. Bureau of Labor Statistics. Labor Force Statistics from the Current Population Survey. Available at: https://www.bls.gov/cps/, 2019. (Accessed 3 August 2018)
37. Munnell, A.H., The average retirement age—an update. 2015. 15-4. Available at: http://crr.bc.edu/wp-content/uploads/2015/03/IB_15-4_508_rev.pdf. (Accessed 3 August 2018)
38. Partridge, J.C., Robertson, K.R., Rogers, E.E., et al. Resuscitation of neonates at 23 weeks' gestational age: a cost-effectiveness analysis. J Matern Fetal Neonatal Med 28 (2015), 121–130.
39. Yieh, L., Dukhovny, D., Zhou, C.G., Gievers, L., Caughey, A.B., Cost effectiveness of neonatal resuscitation at 22 weeks of gestation. Obstet Gynecol 133 (2019), 1199–1207.
40. Townsend, C.L., Cortina-Borja, M., Peckham, C.S., de Ruiter, A., Lyall, H., Tookey, P.A., Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 22 (2008), 973–981.
41. European Collaborative Study. Mother-to-child transmission of HIV Infection in the era of highly active antiretroviral therapy. Clin Infect Dis 40 (2005), 458–465.
42. Kennedy, C.E., Yeh, P.T., Pandey, S., Betran, A.P., Narasimhan, M., Elective cesarean section for women living with HIV: a systematic review of risks and benefits. AIDS 31 (2017), 1579–1591.
43. Read, J.S., Newell, M.K., Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1. Cochrane Database Syst Rev, 4, 2005, Cd005479.
44. Nachega, J.B., Uthman, O.A., Anderson, J., et al. Adherence to antiretroviral therapy during and after pregnancy in low-, middle and high income countries: a systematic review and meta-analysis. AIDS 26 (2012), 2039–2052.
45. Chen, K.T., Sell, R.L., Tuomala, R.E., Cost-effectiveness of elective cesarean delivery in human immunodeficiency virus-infected women. Obstet Gynecol 97 (2001), 161–168.
46. Halpern, M.T., Read, J.S., Ganoczy, D.A., Harris, D.R., Cost-effectiveness of cesarean section delivery to prevent mother-to-child transmission of HIV-1. AIDS 14 (2000), 691–700.
47. Kapogiannis, B.G., Soe, M.M., Nesheim, S.R., et al. Mortality trends in the US Perinatal AIDS Collaborative Transmission Study (1986-2004). Clin Infect Dis 53 (2011), 1024–1034.